MUSSALLEM MICHAEL A 4

4 · Edwards Lifesciences Corp · Filed Mar 4, 2024

Form 4

Period: 2024-03-04

DirectorChairman & CEO

Transactions

Exercise/Conversion
Common Stock
2024-03-04$36.75/sh+29,350$1,078,613→ 33,835.82 total
Sale
Common Stock
2024-03-04$86.21/sh−13,310$1,147,455→ 20,525.82 total
Sale
Common Stock
2024-03-04$87.05/sh−16,040$1,396,282→ 4,485.82 total
Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-03-04−29,350→ 58,700 total
Exercise: $36.75From: 2017-06-11Exp: 2024-05-10→ Common Stock (29,350 underlying)

Holdings

Footnotes (3)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
[F2]This transaction was executed in multiple trades at prices ranging from $85.62 to $86.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $86.63 to $87.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file